Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siHES1 + GSK3b
- Development stage
- Preclinical
- Lead developer
- Otologic Pharmaceutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Otic
01
Overview
siHES1 + GSK3b (also known as Autigen siHES1+GSK3b) is a preclinical-stage siRNA combination therapy being developed by Otologic Pharmaceutics for the treatment of Sensorineural Hearing Loss (SNHL). The therapeutic employs a dual mechanism of action by combining two small interfering RNAs (siRNAs): one targeting HES1 mRNA and another targeting GSK3b (Glycogen Synthase Kinase 3 Beta) mRNA. HES1 is a transcriptional repressor in the Notch signaling pathway, which is involved in the immune response and sensory hair cell loss following acoustic trauma. By simultaneously knocking down HES1 and GSK3b, the therapy aims to stimulate the regeneration of inner ear hair cells or protect existing ones from damage. The program is currently available for partnering or out-licensing.
- Other names
- Autigen siHES1+GSK3b
02
Targets
HES1 (Hairy and Enhancer of Split 1 Protein)GSK3 (Glycogen synthase kinase 3 beta)
Beyond the preview
Go deeper on siHES1 + GSK3b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siHES1 + GSK3b.